MAPK13-IN-1   Click here for help

GtoPdb Ligand ID: 11096

Synonyms: compound 61 [WO2014015056A2]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This compound was claimed as a MAPK13 (p38δ) inhibitor in patent WO2014015056A2 [3]. MAPK13-IN-1 was proposed for mucous-reducing activity with application in respiratory diseases like asthma and COPD. It was designed to act by reducing MAPK13 signalling-induced mucous production by airway epithelial cells in response to activation by the pro-inflammatory cytokine, IL-13 [1]. MAPK13-IN-1 binds to MAPK13 in DFG-out mode and exhibits slow dissociation kinetics.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 81.07
Molecular weight 365.19
XLogP 2.71
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(Nc1cc(nn1C)C(C)(C)C)Nc1ccc(cc1)Oc1ccncc1
Isomeric SMILES O=C(Nc1cc(nn1C)C(C)(C)C)Nc1ccc(cc1)Oc1ccncc1
InChI InChI=1S/C20H23N5O2/c1-20(2,3)17-13-18(25(4)24-17)23-19(26)22-14-5-7-15(8-6-14)27-16-9-11-21-12-10-16/h5-13H,1-4H3,(H2,22,23,26)
InChI Key MHSLDASSAFCCDO-UHFFFAOYSA-N
Bioactivity Comments
SARS-CoV-2: p38 MAPK activity has been reported to be upregulated following SARS-CoV-2 infection of host cells in vitro. MAPK13-IN-1 produces an antiviral effect with an IC50 of 4.6 μM [2].
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
mitogen-activated protein kinase 13 Hs Inhibitor Inhibition 6.2 – 7.1 pIC50 - 1,3
pIC50 7.1 (IC50 8.272x10-8 M) [3]
Description: Determined using an IMAP-based biochemical assay.
pIC50 6.2 (IC50 6.2x10-7 M) [1]
mitogen-activated protein kinase 14 Hs Inhibitor Inhibition 5.4 pIC50 - 1
pIC50 5.4 (IC50 3.6x10-6 M) [1]